Mosby's 2014 Nursing Drug Reference (50 page)

atovaquone/proguanil

(a-toe′va-kwon)

Malarone

Func. class.:
Antiprotozoal

Chem. class.:
Aromatic diamide derivative

ACTION:

The constituents of Malarone, atovaquone, and proguanil hydrochloride interfere with 2 different pathways involved in DNA/RNA synthesis in protozoa

USES:

Malaria, malaria prophylaxis

CONTRAINDICATIONS:

Hypersensitivity to this product, malaria prophylaxis in patients with severe renal impairment

Precautions:
Pregnancy (C), breastfeeding, children, hepatic/GI/renal disease

DOSAGE AND ROUTES
Calculator
Treatment of acute, uncomplicated
P. falciparum
malaria malarone adult strength tabs

• Adult/adolescent/child >40 kg: PO
4 adult strength tabs every day as a single dose × 3 consecutive days

• Child 31-40 kg: PO
3 adult strength tabs every day as a single dose × 3 consecutive days

• Child 21-30 kg: PO
2 adult strength tabs every day as a single dose × 3 consecutive days

• Infant/child 11-20 kg: PO
1 adult strength tab every day × 3 consecutive days

Malarone Pediatric Tabs

• Infant/child 11-20 kg: PO
4 pediatric tabs every day × 3 consecutive days

• Infant/child 9-10 kg: PO
3 pediatric tabs every day × 3 consecutive days

• Infant/child 5-8 kg: PO
2 pediatric tabs every day every 3 consecutive days

P. falciparum
malaria prophylaxis, including chloroquine resistance areas

• 
Each Malarone adult strength tab contains atovaquone 250 mg/proguanil 100 mg; Malarone Pediatric tablet contains atovaquone 62.5 mg/proguanil 25 mg

Malarone adult strength tabs

• Adult/adolescent/child >40 kg: PO
1 adult strength tab every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area

Malarone Pediatric Tab

• Child 31-40 kg: PO
3 pediatric tabs every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area

• Child 21-30 kg: PO
2 pediatric tabs every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area

• Infant/child 11-20 kg: PO
1 pediatric tab every day; begin prophylaxis 1-2 days before entering the endemic area; continue daily during the stay and for 7 days after leaving the area

Available forms:
Tabs (adult) 250 mg atovaquone/proguanil 100 mg; tabs (pediatric) 62.5 atovaquone/proguanil 25 mg

Administer

• 
Give with food or with milk or milk-based drink (nutritional supplement shake) to enhance oral absorption of atovaquone; food with high fat content is desired

• 
Give dose at the same time each day, administer a repeat dose if vomiting occurs within 1 hour after dosing

• 
Tabs may be crushed and mixed with condensed milk for children unable to swallow whole tablets

SIDE EFFECTS

CNS:
Dizziness, headache, anxiety, insomnia
, asthenia, fever

CV:
Hypotension

GI:
Nausea, vomiting, diarrhea
, anorexia, increased AST/ALT,
acute pancreatitis,
constipation, abdominal pain

HEMA:
Anemia, neutropenia

INTEG:
Pruritus, urticaria,
rash

META:
Hyperkalemia, hypoglycemia, hyponatremia

OTHER:
Cough, dyspnea

PHARMACOKINETICS

Atovaquone excreted unchanged in feces (94%), highly protein bound (99%), Protaguanil 75% protein bound, 40%-60% excreted in urine, hepatic metabolism; half-life 2-3 days

INTERACTIONS

Increase:
Level of indinavir

Decrease:
Effect of atovaquone-rifampin, rifabutin, tetracycline, metoclopramide

Increase:
AST, ALT, alk phos

Decrease:
Glucose, neutrophils, Hgb, sodium

NURSING CONSIDERATIONS
Assess:

• 
Malaria:
Identify when the patient will be entering an area with malaria

• 
Bowel pattern before, during treatment

• 
Respiratory status: rate, character, wheezing, dyspnea; risk for respiratory infection

• 
Allergies before treatment, reaction to each medication

• 
CBC, LFTs, serum amylase, creatinine/BUN, sodium; increases in LFTs can persist for 4 wk after discontinuation of treatment

Evaluate:
Therapeutic response:

• 
Resolution/prevention of malaria

Teach patient/family:

• 
To take with food to increase plasma concentrations

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

RARELY USED
atracurium (Rx)

(a-tra-kyoor′ee-um)

Func. class.:
Neuromuscular blocker (nondepolarizing)

USES:

Facilitation of endotracheal intubation, skeletal muscle relaxation during mechanical ventilation, surgery, or general anesthesia

CONTRAINDICATIONS:

Hypersensitivity

 

Black Box Warning:

Respiratory insufficiency

DOSAGE AND ROUTES
Calculator

• Adult and child >2 yr: IV BOL
0.4-0.5 mg/kg then 0.08-0.1 mg/kg 20-45 min after 1st dose if needed for prolonged
procedures; give smaller doses with halothane

• Child 1 mo-2 yr: IV BOL
0.3-0.4 mg/kg

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

HIGH ALERT
atropine (Rx)

(a′troe-peen)

Atreza, AtroPen, Sal-Tropine

Func. class.:
Antidysrhythmic, anticholinergic parasympatholytic, antimuscarinic

Chem. class.:
Belladonna alkaloid

Do not confuse:
atropine
/Akarpine

ACTION:

Blocks acetylcholine at parasympathetic neuroeffector sites; increases cardiac output, heart rate by blocking vagal stimulation in heart; dries secretions by blocking vagus

USES:

Bradycardia <40-50 bpm, bradydysrhythmia, reversal of anticholinesterase agents, insecticide poisoning, blocking cardiac vagal reflexes, decreasing secretions before surgery, antispasmodic with GU, biliary surgery, bronchodilator, AV heart block

Unlabeled uses:
Cardiac arrest, CPR, diarrhea, pulseless electrical activity, ventricular asystole, asthma

CONTRAINDICATIONS:

Hypersensitivity to belladonna alkaloids, closed-angle glaucoma, GI obstructions, myasthenia gravis, thyrotoxicosis, ulcerative colitis, prostatic hypertrophy, tachycardia/tachydysrhythmias, asthma, acute hemorrhage, severe hepatic disease, myocardial ischemia, paralytic ileus

Precautions:
Pregnancy (C), breastfeeding, children <6 yr, geriatric patients, renal disease, CHF, hyperthyroidism, COPD, hypertension, intraabdominal infection, Down syndrome, spastic paralysis, gastric ulcer

DOSAGE AND ROUTES
Calculator
Bradycardia/bradydysrhythmia

• Adult: IV BOL
0.5-1 mg given q3-5min, max 3 mg

• Child: IV BOL
0.01 mg/kg up to 0.4 mg or 0.3 mg/m
2
; may repeat q4-6hr; min dose 0.1 mg to avoid paradoxical reaction, max single dose 0.5 mg

Organophosphate poisoning

• Adult and child: IM/IV
1-2 mg hourly until muscarinic symptoms disappear; may need 6 mg every hr

• Adult and child >90 lb, usually >10 yr: AtroPen
2 mg

• Child 40-90 lb, usually 4-10 yr: AtroPen
1 mg

• Child 15-40 lb: AtroPen
0.5 mg

• Infant <15 lb: IM/IV
0.05 mg/kg q5-20min as needed

Presurgery

• Adult and child >20 kg: SUBCUT/IM/IV
0.4-0.6 mg 30-60 min before anesthesia

• Child <20 kg: IM/SUBCUT
0.01 mg/kg up to 0.4 mg 1/2-1 hr preop, max 0.6 mg/dose

Other books

Twinmaker by Williams, Sean
Undercover by Bill James
Destined (Vampire Awakenings) by Davies, Brenda K.
Surrender To Sultry by Macy Beckett
Considerations by Alicia Roberts
Can't Get Enough by Tenille Brown
Blame It on Paradise by Crystal Hubbard